Saralasin is an angiotensin II receptor antagonist that lowers blood pressure in renin-dependent animal models and may be useful for studying CNS-mediated natriuretic effects.
May guide saralasin use in renin-activated animal models; leaves open human translational relevance.
Saralasin is the only marketed member of a class of compounds described as angiotensin II receptor antagonists. Its pharmacology is characterized by three general properties: (1) no actions unrelated to the renin‐angiotensin system; (2) a small partial agonist effect in some tissues in vitro and in some animal models in vivo, and (3) a blood‐pressure lowering response to saralasin evident only in animals with an activated endogenous renin angiotensin system. It is suggested that the natriuretic effect of angiotensin II mediated via central nervous system (CNS) mechanisms may be future productive area of research in which to study the actions of angiotensin II antagonists.
No takes yet. Share an insight, caveat, or question.
Moore et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: